These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 29158814)

  • 21. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.
    Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y
    J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
    Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
    Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
    Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
    Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
    Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
    Chen Y; Wang L; Zhou J
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
    Liu Y; Niu Z; Lin X; Tian Y
    Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
    Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
    Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
    van Jaarsveld MT; van Kuijk PF; Boersma AW; Helleman J; van IJcken WF; Mathijssen RH; Pothof J; Berns EM; Verweij J; Wiemer EA
    Mol Cancer; 2015 Nov; 14():196. PubMed ID: 26576679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
    Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
    Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
    Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
    Song L; Li Y; Li W; Wu S; Li Z
    J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression.
    Li B; Wang W; Li Z; Chen Z; Zhi X; Xu J; Li Q; Wang L; Huang X; Wang L; Wei S; Sun G; Zhang X; He Z; Zhang L; Zhang D; Xu H; El-Rifai W; Xu Z
    Cancer Lett; 2017 Dec; 410():212-227. PubMed ID: 28965855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
    Wang X; Zhu J
    Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
    Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
    Li B; Chen H; Wu N; Zhang WJ; Shang LX
    Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.